US-based Zenas BioPharma closes upsized Series C round at $200m

US-based Zenas BioPharma closes upsized Series C round at $200m

Edited by: Joymitra Rai

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter